Mallinckrodt, the U.K.-based pharmaceutical company that has its U.S. headquarters in the St. Louis area, has seen its share price hit 52-week lows in recent weeks amid heightened scrutiny of Acthar, its top revenue-generating drug.
A report from analysts at Leerink Partners forecasted declining sales for Acthar, an injectable drug used to treat conditions including multiple sclerosis and infantile spasms, due to potential competition and resistance from payers.
It’s not the first time Acthar has drawn attention for its price. The drug was one of the most costly in the Medicare program, according to a study released last year.
The new Leerink report compounds issues raised by a whistleblower lawsuit. In a suit filed April 10, a former employee alleges she was fired for raising concerns about Acthar.
Read more: St. Louis Post-Dispatch